

# The long-term effects of occupational exposure to vinyl chloride monomer on microcirculation: a cross-sectional study 15 years after retirement

Vincent Lopez,<sup>1</sup> Alain Chamoux,<sup>1</sup> Marion Tempier,<sup>2</sup> H el ene Thiel,<sup>3</sup> Sylvie Ughetto,<sup>4</sup> Marion Trousselard,<sup>5</sup> Geraldine Naughton,<sup>6</sup> Fr ed eric Dutheil<sup>1,6,7</sup>

**To cite:** Lopez V, Chamoux A, Tempier M, *et al*. The long-term effects of occupational exposure to vinyl chloride monomer on microcirculation: a cross-sectional study 15 years after retirement. *BMJ Open* 2013;**3**:e002785. doi:10.1136/bmjopen-2013-002785

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2013-002785>).

Received 27 February 2013  
Revised 23 April 2013  
Accepted 24 April 2013

This final article is available for use under the terms of the Creative Commons Attribution Non-Commercial 2.0 Licence; see <http://bmjopen.bmj.com>

For numbered affiliations see end of article.

**Correspondence to**  
Dr Fr ed eric Dutheil;  
[fred\\_dutheil@yahoo.fr](mailto:fred_dutheil@yahoo.fr)

## ABSTRACT

**Objectives:** To assess residual long-term microcirculation abnormalities by capillaroscopy, 15 years after retiring from occupational exposure to vinyl chloride monomer (VCM).

**Design:** Cross-sectional study.

**Setting:** Allier, one of the major areas of polyvinyl chloride production in France.

**Participants:** We screened 761 (97% men) retired workers exposed to chemical toxics. Exposure to chemicals other than VCM excluded potential participants.

**Primary and secondary outcome measures:** These participants underwent a medical examination including a capillaroscopy, symptoms of Raynaud and comorbidities, as well as a survey to determine exposure time, direct or indirect contact, type of occupation, smoking status and time after exposure. A double blind analysis of capillaroscopic images was carried out. A control group was matched in age, sex, type of occupation.

**Results:** 179/761 retired workers were only exposed to VCM at their work, with 21 meeting the inclusion criteria and included. Exposure time was 29.8 ±1.9 years and time after exposure was 15.9±2.4 years. Retired workers previously exposed to VCM had significantly higher capillaroscopic modifications than the 35 controls: enlarged capillaries (19% vs 0%, p<0.001), dystrophy (28.6% vs 0%, p=0.0012) and augmented length (33% vs 0%, p<0.001). Time exposure was linked (p<0.001) with enlarged capillaries (R<sup>2</sup>=0.63), dystrophy (R<sup>2</sup>=0.51) and capillary length (R<sup>2</sup>=0.36). They also had higher symptoms of Raynaud (19% vs 0%, p=0.007) without correlation with capillaroscopic modifications.

**Conclusions:** Although VCM exposure was already known to affect microcirculation, our study demonstrates residual long-term abnormalities following an average of 15 years' retirement, with a time-related exposure response. Symptoms of Raynaud, although statistically associated with exposure, were not related to capillaroscopic modifications; its origin remains to be determined.

## ARTICLE SUMMARY

### Article focus

- Vinyl chloride monomer (VCM) exposure induces microcirculation abnormalities, which can be diagnosed by capillaroscopy.
- Residual long-term abnormalities following retirement required investigation.

### Key messages

- Our results demonstrated residual long-term abnormalities following an average of 15 years' retirement, with a time-related exposure response.
- Symptoms of Raynaud, although statistically associated with exposure, were not related to capillaroscopic modifications; its origin remains to be determined.

### Strengths and limitations of this study

- The strong points are that this study had a rigorous selection criteria of exclusively VCM exposed participants, avoided confounding factors and focused on retired workers of at least 15 years after the end of occupational VCM exposure.
- The main limitation is that the pathophysiology of Raynaud after VCM exposure remains unclear.

## INTRODUCTION

Vinyl chloride monomer (VCM) is primarily used in the manufacture of plastics and also serves as a raw material in organic synthesis. VCM is an aliphatic hydrocarbon also known as chloroethene. Its polymerisation leads to a synthetic resin called polyvinyl chloride, commonly abbreviated as PVC. PVC is the third most widely produced plastic, after polyethylene and polypropylene.<sup>1</sup> PVC can be made softer and more flexible by the addition of phthalates, and may also replace rubber. Thus, PVC is widely used as follows: pipes and water distribution, a substitute for painted wood (eg, window frames, sills, flooring), electrical cable insulation, inflatable

products, waterproof clothing (eg, coats, skiing equipment, shoes), healthcare products (eg, containers, tubing, catheters), food packaging, dental appliances and vinyl records.<sup>1</sup>

Harmless in its polymeric form, workers handling the finished PVC product are perfectly safe. In contrast, the at-risk phase lies in the manual descaling of autoclaves used for the polymerisation where workers can come into contact with it during its monomer state.<sup>2</sup> Chronic intoxication by the gaseous monomer VCM is linked to several symptoms such as:<sup>3</sup> asthenia and dizziness,<sup>3</sup> Raynaud's syndrome,<sup>4, 5</sup> digestive ulcers with nausea and anorexia,<sup>3</sup> systemic symptoms of arthralgia and myalgia,<sup>3</sup> trophic cutaneous symptoms and sclerosis. It has also been suspected in the onset of acroosteolysis<sup>4, 6, 7</sup> and hepatocellular carcinoma.<sup>8, 9</sup> More generally, VCM exposure involves chromosomal aberrations and increased carcinogenic risk.<sup>10</sup> Even if VCM-related diseases may have a genetic base, they are also linked to prolonged occupational VCM exposure.<sup>5, 11</sup>

Scleroderma-like microvascular abnormalities have also been described on exposed workers.<sup>12-14</sup> The most common and non-invasive means of investigating these abnormalities is capillaroscopy. The widespread identification of individuals most at risk could enable early detection and management strategy.<sup>15</sup> The residual effects of VCM on microcirculation have been shown only once on 15 workers who had ceased their VCM exposure 6 months prior to testing.<sup>13</sup> However, the residual and long-term abnormalities following retirement are unknown. Our hypothesis was that higher capillaroscopic abnormalities would be found in the VCM exposed group than in the control group.

Therefore, the aim of our cross-sectional study was to investigate residual and long-term capillaroscopic abnormalities following retirement, after 15 years without VCM exposure.

## METHODS

### Participants

We enrolled male retired workers exposed to VCM in PVC production. They provided written informed consent. The study was approved by the human ethics committees from the Clermont-Ferrand University Hospital, France. To be eligible, participants had to be: male (due to the male dominance in this workforce), retired, aged over 60 years, with at least a 5-year occupational exposure to VCM, a time after VCM exposure of at least 5 years, and no exposure to chemicals other than VCM. Moreover, participants with diabetes mellitus were also excluded as it might interfere with microcirculation,<sup>16-21</sup> as well as individuals declaring the use or previous use of treatments that might alter microcirculation.

Participants responded to a survey to determine exposure time, direct or indirect contact, type of occupation, time after exposure and smoking history. They underwent a medical examination including a capillaroscopy,

symptoms of Raynaud and comorbidities such as pathologies that may interfere with microcirculation (arterial hypertension, dyslipidaemia) or pathologies potentially linked with VCM exposure (cardiovascular or respiratory diseases).<sup>22</sup>

A control group was matched in age, sex, type of occupation. They were recruited via advertisements. Selection criteria for this group also included no occupational or leisure chemical exposure, and no diabetes mellitus.<sup>16-21</sup>

### Capillaroscopy

A nailfold capillaroscopy was performed on all fingers of each patient, excluding the thumbs.<sup>23</sup> The nailfold capillaroscopies of the fingers were captured in images and electronically stored. The same investigator conducted all the capillaroscopies. A double blind analysis of capillaroscopic images was completed on de-identified data.

The outcomes were the five following classical criteria used in capillaroscopy: density, length, diameter, dystrophy and haemorrhage. Criteria for abnormalities were defined as follows: decreased capillary density <10/mm (avascular zone <7/mm),<sup>24</sup> augmented capillary length >300 µm,<sup>24, 25</sup> increased capillary diameter >25 µm<sup>25</sup> (megacapillary >50 µm)<sup>26, 27</sup> and dystrophy was associated with capillary branching >15%.<sup>28</sup> Haemorrhage is defined as the microvascular extravasation of the red blood cells linked to the damage of the vessel wall.<sup>27</sup>

### Statistics

Data are presented as the mean percentage change and SD.

The main judgement criterion for abnormal microcirculation was the presence of at least one abnormality in capillaroscopy. Under the assumption of similar proportions of abnormalities as that reported during a VCM exposure,<sup>12-14</sup> our sample calculation indicated that we would need 27 participants in each of the exposed and non-exposed groups to find a change in probability of 35% (ie, 40% in exposed vs 5% in non-exposed) for a power of 80% and a two-sided  $\alpha$  of 5%. When we considered an exposed to non-exposed sample ratio of 1 : 2, 19 and 38 participants, respectively, were needed in the exposed and non-exposed groups. Under the assumption of 0% prevalence in the non-exposed group, sample sizes of 13 exposed and 26 non-exposed were required.

Statistical analyses were performed with SPSS software, V.19. Correlations were used for interobserver reliability. The Gaussian distribution for each parameter was assessed by a Shapiro-Wilk test. Comparisons between groups (exposed vs control) were made through the usual tests:  $\chi^2$  test for categorical variables (or Fisher's exact test where appropriate) and Student t test for quantitative variables (or Kruskal-Wallis if assumptions of normal distribution were violated). Significance was accepted for a  $p < 5\%$ . The links between continuous variables were analysed using linear regression. The links between binary and continuous variables were analysed

with logistic regression (Nagelkerke R Square). Multivariate models were used to predict the relationship between the capillary parameters and other parameters such as exposure time and time after exposure.

**RESULTS**

**Participants**

We screened 761 (97% men) retired workers exposed to chemical toxics from two leading enterprises involved in PVC production (n=435 and n=91), as well as participants from many subcontracting companies (n=235), also known to have been exposed to VCM. The strict selection criteria of exposure only to VCM reduced the sample size to 21 (figure 1).

Thirty-five age-matched controls were also recruited without occupational or leisure time exposure to chemical toxics.

**Main capillaroscopic outcomes**

There were no missing data. Inter-rater reliability was confirmed with correlations exceeding 0.70 for each parameter. The mean of the values of the two investigators is presented in table 1. Concerning the qualitative data,

when a disagreement occurred, the two observers again analysed the data together and requested the opinion of a third expert. The disagreement occurred only for two decreased capillary density <10/mm, and one capillary branching >15%.

Compared with controls, retired workers previously exposed to VCM had higher capillaroscopic abnormalities: enlarged capillaries (0% vs 19%, p<0.001), dystrophy (0% vs 28.6%, p=0.0012; figure 2) and augmented length (0% vs 33%, p<0.001). The mean length was 15% higher in the exposed group than in controls (p=0.020), as well as having a 12% greater diameter of the capillaries (p=0.006; table 1).

**Exposure**

Exposure time was 29.8±1.9 years and time after exposure was 15.9±2.4 years. Time of exposure to VCM was strongly linked with enlarged capillaries (Nagelkerke R Square approximation of 63%, p<0.001), with dystrophy (Nagelkerke R Square approximation of 51%, p<0.001), and modestly linked with capillary length expressed as binary data (Nagelkerke R Square approximation of 36%, p<0.001) or as quantitative data (R<sup>2</sup>=8%; p=0.031; table 1). Age was not associated with capillaroscopic




Figure 1 Participant flow chart.

abnormalities. No multivariate models improved the results from simple regressions.

**Symptoms of Raynaud**

The VCM exposed group also had more symptoms of Raynaud (19% vs 0%, p=0.007) independent of the capillaroscopic modifications (table 1).

**Comorbidities and smoking**

Neither the respiratory nor the cardiovascular diseases were associated with VCM exposure. However, we combined both groups to explore the potential associations between the capillaroscopic parameters and high blood pressure, dyslipidaemia and smoking. Capillary length in the participants medicated for arterial hypertension (n=20/61) did not differ from that in participants without hypertension. Participants treated with lipid lowering drugs with dyslipidaemia (n=10/61) showed a trend for a higher capillary length than participants

without dyslipidaemia (p=0.079). Finally, there were no capillaroscopic differences between smokers and non-smokers. However, smokers who had been exposed to VCM tended to have a higher capillary length than non-smokers (p=0.073).

**DISCUSSION**

**Principal findings of the study**

Changes in microcirculation persist for at least 15 years following occupational VCM exposure, with a time-related exposure response. Symptoms of Raynaud, although statistically associated with exposure, were not related to pathological capillaroscopic changes.

**What the study adds**

The microcirculation changes following VCM exposure have been previously shown on 15 workers who ceased their occupational exposure 6 months prior to testing.<sup>13</sup>


**Table 1** Characteristics of participants, exposure to VCM and capillaroscopic outcomes

	Retired from exposure to VCM (n=21)	Controls (n=40)	p Value
Age (years)	74.4±2.9	76.3±3.2	NS
Type of occupation: blue collar workers, 'manual'	100%	100%	NS
Exposure to VCM			
Direct contact with VCM	100%	0	<0.001
Exposure time (years)	29.8±1.9	0	<0.001
Time after exposure (years)	15.9±2.4	–	–
Main capillaroscopic outcomes			
Density			
Mean density (mm)	8.6±0.4	8.8±0.3	NS
Decreased capillary density <10/mm (n (%))	9 (43)	16 (46)	NS
Avascular zone <7/mm (n (%))	0	0	NS
Length			
Mean length (µm)	291±14	254±9	0.020
Augmented capillary length >300 µm (n (%))	7 (33)	0	<0.001
Diameter			
Mean diameter of capillaries (µm)	28.9±0.9	25.7±0.6	0.006
Enlarged capillaries >25 µm (n (%))	4 (19)	0	0.007
Megacapillary >50 µm (n (%))	0	0	NS
Dystrophy			
Capillary branching >15% (n (%))	6 (29)	0	<0.001
Haemorrhage (n (%))	0	0	NS
Symptoms of Raynaud			
n (%) with Raynaud	4 (19)	0	0.007
Participants with medications which could induce Raynaud (n (%))	2 (9)	4 (11)	NS
Other causes of Raynaud	0	0	NS
Comorbidities			
Respiratory diseases	2 (9)	6 (17)	NS
Cardiovascular diseases (except high blood pressure)	4 (19)	5 (14)	NS
Myocardial infraction	3 (14)	3(9)	NS
Routine medications, n (%) of patients treated for			
Blood pressure	7 (33)	13 (37)	NS
Lipid lowering	4 (19)	6 (17)	NS
Smoking (n (%))	9 (43)	18 (51)	NS

VCM, vinyl chloride monomer.



**Figure 2** Normal capillaroscopy on a control participant (A) and capillaroscopy with dystrophia >15% on a retired worker exposed to vinyl chloride monomer for 37 years, with no treatment and no comorbidity, non-smoking (B).



Our study supports these results over a longer period following VCM exposure—15 years.

The dose responsiveness of VCM exposure and compromised capillarisation is generally,<sup>13</sup> but not always,<sup>12</sup> reported. Although daily VCM doses may have been more informative, the current study was restricted to years of exposure. Thus, we are limited to describing associations with an exposure time—response rather than a dose-response. The number of years of exposure is an easy question for physicians to ask of workers during risk assessment protocols.

The absence of changes in microcirculation on less exposed workers<sup>29</sup> resulted in a suggestion that a threshold of exposure exists. This finding is supported by previous studies showing that long-term exposure (>8 years) induced greater chromosomal aberrations.<sup>10 30</sup> Further, not all workers exposed to VCM develop microvascular abnormalities, suggestive of an underlying genetic susceptibility (polymorphism of glutathione S-transferase).<sup>5 11</sup> A finding that female VCM-exposed workers were more susceptible than males to the risk of increased chromosome damage also reinforced the genetic susceptibility theory.<sup>30</sup>

### Comparison with other studies

After 50 years of age, minor dystrophies could alter the readability and interpretation of capillaroscopic analyses.<sup>31</sup> Nevertheless, we controlled this parameter by matching the exposed group and the controls on age and we conducted a double-blind analysis by two experienced readers. Moreover, capillaroscopic abnormalities among workers exposed to VCM in the present study were not influenced by age.<sup>13</sup>

VCM has been suspected to cause respiratory and circulatory diseases.<sup>32</sup> However, the similar frequencies of these diseases in both groups do not support this hypothesis.

Diabetes mellitus,<sup>16–21</sup> high blood pressure,<sup>18 33–35</sup> dyslipidaemia<sup>34</sup> or some comorbidities/medications<sup>22</sup> could interfere with microcirculation. Diabetes mellitus was an exclusion criterion and thus could not interfere with our results. Perhaps due to the low numbers of participants, our results failed to support previous findings of

compromised microcirculation in participants treated for arterial hypertension.<sup>18 33–35</sup> The trend for increased capillary length observed in our participants treated with lipid-lowering drugs could be a response to increased peripheral vascular resistance, in order to maintain their function of metabolic exchange.<sup>35</sup> Similarly, smoking could induce a decrease in tissue perfusion,<sup>36</sup> and dystrophia.<sup>37</sup> We did not observe differences between smokers and non-smokers, with the exception of a trend for abnormal microcirculation among smokers exposed to VCM. The potential of a synergistic effect of tobacco and VCM-exposure warrants further investigations. It should be noted that VCM exposure in the current study was more strongly associated with compromised microcirculation than high blood pressure, dyslipidaemia and smoking.

Previous research into the links between systemic sclerosis and VCM exposure is limited by a single case design<sup>38</sup> and a somewhat dated analyses of a population exposed to solvents.<sup>39</sup> The broader use of a term such as solvents is less specific than the VCM exposure carefully isolated for investigation in the present study.

A higher prevalence of symptoms of Raynaud has been established in workers with VCM exposure,<sup>32</sup> up to one-third of the exposed workers.<sup>13</sup> The comparison between studies with different selection criteria and different sample sizes is difficult. There is also the possibility of selection bias in non-randomised recruitment. Within these limitations, our results support previous data, and extend knowledge by demonstrating that the prevalence of symptoms of Raynaud remained higher at least 15 years following VCM exposure. Furthermore, in the current study, all the participants who suffered from symptoms of Raynaud had never taken medications or suffered from other diseases conducive to Raynaud.

### Unanswered questions

Although symptoms of Raynaud are statistically associated with VCM exposure, we could not report a link with capillaroscopic modifications. The pathophysiology of Raynaud's phenomenon remains unknown. There seems to be primary or secondary vascular failure influenced by a hereditary factor.<sup>40</sup> Decreased perfusion

pressure could be secondary to systemic hypotension or be caused by proximal arterial occlusion, influenced by many factors; both vascular and intra vascular, neural, environmental or hereditary.<sup>41</sup> Angiography of the hands of patients exposed to VCM showed occlusions, stenosis and narrowing of the distal arteries with the development of collateral circulation.<sup>42</sup> Lack of statistical power in our study could contribute to the lack of relationship between the capillaroscopic changes and symptoms of Raynaud.

### Strengths and limitations of the study

This study presents some major strengths: a rigorous selection criteria of exclusively VCM-exposed participants avoided confounding factors, well-matched controls, a double blind analyses, sufficient number of participants to detect the capillaroscopic differences between groups, the focus on retired workers at least 15 years after the end of occupational VCM exposure. The attendance rate of 30% (53 of 179 individuals exclusively exposed to VCM at work agreed to participate in our study)<sup>43–47</sup> seems very high compared with other studies, taking into account their age (75 years), distance from the location of the medical examination (averaging approximately 80 km), and that no financial compensation was offered.

There are limitations to this study. The cross-sectional design has limitations; however, proof of concept was important and achieved (with a possibility of longitudinal follow-up). Differences in some but not all capillary outcomes may be explained by a lack of statistical power. The results are insufficient to propose guidelines for all workers exposed to VCM. More accurate quantifiable measures of VCM exposure are not available; however, for the purpose of this study, we used industry established lists of exposure legally required in France. The pathophysiology of Raynaud after VCM exposure remains unclear. A further limitation may lie in the fact that most of the retired workers exposed to VCM were from the same enterprise; thus, potentially more at-risk manufacturing processes remained undetected. Gender specificity may warrant future studies.

### CONCLUSION

Although VCM exposure was already known to affect microcirculation, our study demonstrated the potential for residual long-term abnormalities following an average of 15 years' retirement, with a time exposure response. Symptoms of Raynaud, although statistically associated with exposure, were not associated with capillaroscopic modifications; its origin remains to be determined. Future research could focus on other chemical products that have a similar structure than VCM and more extensive research on the type of occupations at risk of VCM exposure.

### Author affiliations

<sup>1</sup>Department of Occupational Medicine, University Hospital CHU G. Montpied, Clermont-Ferrand, France

<sup>2</sup>Department of Radiopharmacy, University Hospital CHU G. Montpied, Clermont-Ferrand, France

<sup>3</sup>Department of Vascular Medicine, University Hospital CHU G. Montpied, Clermont-Ferrand, France

<sup>4</sup>Department of Medical Information—Clinical research and innovation direction, University Hospital CHU G. Montpied, Clermont-Ferrand, France

<sup>5</sup>Neurophysiology of emotions, ENOP Department, CRSSA/IRBA, La Tronche, France

<sup>6</sup>School of Exercise Science, Australian Catholic University, Fitzroy, Australia

<sup>7</sup>Laboratory of Metabolic Adaptations to Exercise in Physiological and Pathological conditions (AME2P, EA3533), Blaise Pascal University, Clermont-Ferrand, France

**Acknowledgements** The authors would like to thank Dr George Mnatzaganian for help with statistics (Faculty of Health Sciences, Australian Catholic University, Fitzroy, Victoria, Australia, email: George.Mnatzaganian@acu.edu.au). They also want to acknowledge the 'Association of the sick from chemicals' (Association des Malades de la Chimie), 15 Av Albert Poncet 03410 Domerat, France, which helped us recruit the retired workers from VCM exposure.

**Contributors** VL has participated as an MD student and principal investigator. FD and AC obtained research funding and generated the intellectual development of the study. FD knew the potential exposed workers to VCM. VL, FD, AC and SH contributed to the conception of the protocol. VL, FD and SH conducted the data analysis. VL, FD, MT contributed to the drafting of the manuscript. VL recruited all participants and performed all the capillaroscopies. VL and MT completed the double blind analyses of capillaroscopy. FD, AC, VL, GN and MT revised the manuscript. All authors read and approved the final manuscript.

**Funding** The Occupational Medicine department of CHU G. Montpied, Clermont-Ferrand, France funded this study. No other funding source had a role in the design, conduct or reporting of the study.

**Competing interests** None.

**Patient consent** Obtained.

**Ethics approval** The study was approved by the human ethics committees of the Clermont-Ferrand University Hospital, France.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional data are available.

### REFERENCES

- Allsopp M, Giovanni G. *Poly(vinyl chloride) ullmann's encyclopedia of industrial chemistry*. 2000.
- Fontana L, Baietto M, Becker F, *et al*. Clinical and capillaroscopic study of Raynaud's phenomenon in retired patients previously exposed to vinyl chloride monomer. *J Mal Vasc* 1995;20:268–73.
- Veltman G, Lange CE, Juhe S, *et al*. Clinical manifestations and course of vinyl chloride disease. *Ann N Y Acad Sci* 1975;246:6–17.
- Harris DK, Adams WG. Acro-osteolysis occurring in men engaged in the polymerization of vinyl chloride. *BMJ* 1967;3:712–14.
- Fontana L, Marion MJ, Ughetto S, *et al*. Glutathione S-transferase M1 and GST T1 genetic polymorphisms and Raynaud's phenomenon in French vinyl chloride monomer-exposed workers. *J Hum Genet* 2006;51:879–86.
- Preston BJ, Jones KL, Grainger RG. Clinical aspects of vinyl chloride disease: acro-osteolysis. *Proc R Soc Med* 1976;69:284–6.
- Wilson RH, McCormick WE, Tatum CF, *et al*. Occupational acroosteolysis. Report of 31 cases. *JAMA* 1967;201:577–81.
- Dragani TA, Zocchetti C. Occupational exposure to vinyl chloride and risk of hepatocellular carcinoma. *Cancer Causes Control* 2008;19:1193–200.
- Mundt KA, Dell LD, Austin RP, *et al*. Historical cohort study of 10 109 men in the North American vinyl chloride industry, 1942–72: update of cancer mortality to 31 December 1995. *Occup Environ Med* 2000;57:774–81.

10. Kumar AK, Balachandar V, Arun M, *et al.* A comprehensive analysis of plausible genotoxic covariates among workers of a polyvinyl chloride plant exposed to vinyl chloride monomer. *Arch Environ Contam Toxicol* 2013;64:652–8.
11. Ji F, Zhu S, Sun P, *et al.* Relationship between genetic polymorphisms of phase I and phase II metabolizing enzymes and DNA damage of workers exposed to vinyl chloride monomer. *Wei Sheng Yan Jiu* 2009;38:7–11.
12. Langauer-Lewowicka H. Nailfolds capillary abnormalities in polyvinyl chloride production workers. *Int Arch Occup Environ Health* 1983;51:337–40.
13. Maricq HR, Darke CS, Archibald RM, *et al.* In vivo observations of skin capillaries in workers exposed to vinyl chloride. An English-American comparison. *Br J Ind Med* 1978;35:1–7.
14. Maricq HR, Johnson MN, Whetstone CL, *et al.* Capillary abnormalities in polyvinyl chloride production workers. Examination by in vivo microscopy. *JAMA* 1976;236:1368–71.
15. Kowal-Bielecka O, Bielecki M, Kowal K. Recent advances in the diagnosis and treatment of systemic sclerosis. *Polskie Archiwum Medycyny Wewnętrznej* 2013;123:51–8.
16. Pazos-Moura CC, Moura EG, Bouskela E, *et al.* Nailfold capillaroscopy in non-insulin dependent diabetes mellitus: blood flow velocity during rest and post-occlusive reactive hyperaemia. *Clin Physiol* 1990;10:451–61.
17. Iabichella ML, Mariotti R, Nuti M, *et al.* Site specificity of biomicroscopic pattern in diabetic patients. *Minerva Cardioangiologica* 1999;47:619–21.
18. Lambova SN, Muller-Ladner U. The specificity of capillaroscopic pattern in connective autoimmune diseases. A comparison with microvascular changes in diseases of social importance: arterial hypertension and diabetes mellitus. *Mod Rheumatol* 2009;19:600–5.
19. Vayssairat M, Le Devehat C. [Critical analysis of vascular explorations in diabetic complications]. *J Mal Vasc* 2001;26:122–5.
20. Meyer MF, Pfohl M, Schatz H. [Assessment of diabetic alterations of microcirculation by means of capillaroscopy and laser-Doppler anemometry]. *Med Klin (Munich)* 2001;96:71–7.
21. Chang CH, Tsai RK, Wu WC, *et al.* Use of dynamic capillaroscopy for studying cutaneous microcirculation in patients with diabetes mellitus. *Microvasc Res* 1997;53:121–7.
22. Gallucci F, Russo R, Buono R, *et al.* Indications and results of videocapillaroscopy in clinical practice. *Adv Med Sci* 2008;53:149–57.
23. Hern S, Mortimer PS. Visualization of dermal blood vessels—capillaroscopy. *Clin Exp Dermatol* 1999;24:473–8.
24. Ingegnoli F, Gualtierotti R, Lubatti C, *et al.* Feasibility of different capillaroscopic measures for identifying nailfold microvascular alterations. *Semin Arthritis Rheum* 2009;38:289–95.
25. Kabasakal Y, Elvins DM, Ring EF, *et al.* Quantitative nailfold capillaroscopy findings in a population with connective tissue disease and in normal healthy controls. *Ann Rheum Dis* 1996;55:507–12.
26. Bhakuni DS, Vasdev V, Garg MK, *et al.* Nailfold capillaroscopy by digital microscope in an Indian population with systemic sclerosis. *Int J Rheum Dis* 2012;15:95–101.
27. Cutolo M, Pizzorni C, Secchi ME, *et al.* Capillaroscopy. *Best Pract Res Clin Rheumatol* 2008;22:1093–108.
28. Jouanny P, Schmidt C, Feldmann L, *et al.* Focus on a quick reading of nailfold capillaroscopy. *J Mal Vasc* 1994;19:206–9.
29. Przybylowski J, Podolecki A, Laks L, *et al.* [Health status of workers in polyvinyl chloride processing plants. I. Evaluation of occupational exposure. Subjective and capillaroscopy studies. Conduction velocity in the motor nerves]. *Med Pr* 1983;34:385–96.
30. Jiao J, Feng NN, Li Y, *et al.* Estimation of a safe level for occupational exposure to vinyl chloride using a benchmark dose method in central China. *J Occup Health* 2012;54:263–70.
31. Carpentier PH. New techniques for clinical assessment of the peripheral microcirculation. *Drugs* 1999;59:17–22.
32. Laplanche A, Clavel F, Contassot JC, *et al.* Exposure to vinyl chloride monomer: report on a cohort study. *Br J Ind Med* 1987;44:711–15.
33. Prasad A, Dunnill GS, Mortimer PS, *et al.* Capillary rarefaction in the forearm skin in essential hypertension. *J Hypertens* 1995;13:265–8.
34. Bonacci E, Santacroce N, D'Amico N, *et al.* Nail-fold capillaroscopy in the study of microcirculation in elderly hypertensive patients. *Arch Gerontol Geriatr* 1996;22(Suppl 1):79–83.
35. Antonios TF, Singer DR, Markandu ND, *et al.* Structural skin capillary rarefaction in essential hypertension. *Hypertension* 1999;33:998–1001.
36. Lehr HA. Microcirculatory dysfunction induced by cigarette smoking. *Microcirculation* 2000;7:367–84.
37. Lova RM, Miniati B, Macchi C, *et al.* Morphologic changes in the microcirculation induced by chronic smoking habit: a videocapillaroscopic study on the human labial mucosa. *Am Heart J* 2002;143:658.
38. Betta A, Tommasini M, Bovenzi M, *et al.* [Scleroderma and occupational factors: a case-control study and analysis of literature]. *Med Lav* 1994;85:496–506.
39. Ostlere LS, Harris D, Buckley C, *et al.* Atypical systemic sclerosis following exposure to vinyl chloride monomer. A case report and review of the cutaneous aspects of vinyl chloride disease. *Clin Exp Dermatol* 1992;17:208–10.
40. Block JA, Sequeira W. Raynaud's phenomenon. *Lancet* 2001;357:2042–8.
41. Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. *Nat Rev Rheumatol* 2012;8:469–79.
42. Koischwitz D, Marsteller HJ, Lackner K, *et al.* [Changes in the arteries in the hand and fingers due to vinyl chloride exposure (author's transl)]. *Rofo* 1980;132:62–8.
43. Dutheil F, Kelly C, Biat I, *et al.* [Relation between the level of knowledge and the rate of vaccination against the flu virus among the staff of the Clermont-Ferrand University hospital]. *Med Mal Infect* 2008;38:586–94.
44. Chiew M, Weber MF, Egger S, *et al.* A cross-sectional exploration of smoking status and social interaction in a large population-based Australian cohort. *Soc Sci Med* 2012;75:77–86.
45. Penforis A, San-Galli F, Cimino L, *et al.* Current insulin therapy in patients with type 2 diabetes: results of the ADHOC survey in France. *Diabetes Metab* 2011;37:440–5.
46. Heinavaara S, Tokola K, Kurtio P, *et al.* Validation of exposure assessment and assessment of recruitment methods for a prospective cohort study of mobile phone users (COSMOS) in Finland: a pilot study. *Environ Health* 2011;10:14.
47. Eriksen L, Gronbaek M, Helge JW, *et al.* The Danish Health Examination Survey 2007–2008 (DANHES 2007-2008). *Scand J Public Health* 2011;39:203–11.